Heron Therapeutics Stock News

In the last trading session, 1.2 million Heron Therapeutics Inc. (NASDAQ:HRTX) shares changed hands as the companys beta touched 1.33. With the companys per share price at $11.24 changed hands at $0.31 or 2.84% during last session, the market valuation stood at $1.13B. HRTXs last price was a discount, traded about -99.29% off its 52-week Is Heron Therapeutics Inc. (NASDAQ: HRTX) Stock Set To Rise More? Read More »

Analysts forecast that Heron Therapeutics, Inc. (NASDAQ:HRTX) will report sales of $26.68 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Heron Therapeutics earnings. The lowest sales estimate is $24.00 million and the highest is $30.03 million. Heron Therapeutics reported sales of $20.61 million in the same quarter last []

SAN DIEGO, Nov. 11, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treat

Heron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q3 2021 Results - Earnings Call Transcript

These once-promising biotech stocks are trading at a fraction of their all-time highs right now.

After setbacks with the FDA, Heron finally launched Zynrelef in July with a constricted label to market. I believe Zynrelef might struggle in its first few quarters on the market. Heron is looking to

SAN DIEGO, Sept. 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class trea

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -5.08% and -21.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatm

SAN DIEGO, July 28, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatm

Heron Therapeutics Inc (NASDAQ: HRTX) has announced the online publication of a new analysis from the Phase 3 EPOCH 1 and EPOCH 2 studies evaluating Zynrelef (bupivacaine and meloxicam) in adults a

SAN DIEGO, July 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatm

SAN DIEGO, July 6, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treat

SAN DIEGO, July 1, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatme

The White House's plans to address the U.S. opioid crisis could be good news for Heron Therapeutics and Collegium Pharmaceutical, makers of safer pain management drugs.